GlaxoSmithKline has begun a late-stage study testing its experimental antibiotic, gepotidacin, in patients with urinary tract infections and gonorrhoea.
According to GSK, no new class of oral antibiotics for uncomplicated urinary tract infections and urogenital gonorrhoea have been developed and approved in the past 20 years. Gepotidacin is the first of a new class of drugs and is expected to treat the two common bacterial infections, which have been identified as antibiotic resistant threats by U.S. health regulators.
GSK's antibiotic will be compared to a combination of ceftriaxone and azithromycin in about 600 patients with urogential gonorrhoea, and against nitrofurantoin in nearly 1,200 women with urinary tract infections.
Read about GSK's research efforts
